Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors  by Gottlieb, Stephen S. et al.
JACC Vol . 22, No
. 4
October 1993:
9
63 -7
	
463
Sustained Hemodynamic Response to Flosequinan in Patients With
Heart Failure Receiving Angiotensin-Converting Enzyme Inhibitors
STEPHEN S. GOTTLIEB, MD, FACC, MARRICK L
. KUKIN, MD, FACC,* JOSHUA PENN, MD,*
MICHAEL L. FISHER, MD, FACC, MICHELLE CINES, RN, NORMA MEDINA, RN,*
MADELINE YUSHAK, RN,* MARY TAYLOR, RN,* MILTON PACKER, MD, FACC*
Baltimore, Maryland and New York, New York
Objectives . We evaluated the short- and long-tom effects of
Ilosequinan in 47 patients with severe heart failure despite ongoing
captopril treatment .
Background. There have been no previous evaluations of the
long-term hemodynamic effects of any direct-acting vasodilator in
patients with heart failure receiving an angiotensin-converting
enzyme inhibitor. Flosequinan is an arterial and venous vasodila-
tor with actions similar to those of the hydralazine-isosorbide
dinitrate combination.
Methods. After baseline heinowyr:a-nic measurements using
balloon-tipped pulmonary artery and radial arterial catheters,
patients were randomized to receive 50, 100 or 150 mg of
flosequinan daily. Hemodynamic variables were measured imme-
diately before and after short-term flosequinan administration
and after 8 weeks of therapy .
Resulls. With short-term flosequinan administration, mean arte-
rial, right atria] and left ventricular filling pressures decreased by
6.4 t 1 .1, 3.8 * 0.5 and 7.3 t 0.7 mm Hg, respectively (all p <
It has recently been proposed that direct-acting vasodilators
can be utilized as adjunctive therapy for the treatment of
heart failure in patients receiving angiotensin-converting
enzyme inhibitors (1). The results of the second Veterans
Administration Heart Failure Trial (V-HeFT-I1) suggested
that the use of enalapril in patients with heart failure de-
creases mortality more than the use of hydralazine and
isosorbide dinitrate but that the combination of hydralazine
and isosorbide dinitrate might be a better treatment for
increasing exercise capability (2) . Concurrent administration
of an angiotensin-converting enzyme inhibitor and a vasodi-
lator could theoretically maximize both survival and exer-
cise tolerance .
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0.001) . Cardiac index increased by 0 .5 t 0.1 fitersfmin per in,
systemic vascular resistance decreased by 616 t 105 dynes-s-csni s
and heart rate increased by 4 ± 1 beatsrmin (all p < 0.001) . After 8
weeds of long-term flosequinan administration, the vasodilator effect
of a dose of flosequinan persisted. Compared with pretreatment
baseline values, mean arterial, right atrfal and left ventricular
filling pressures at the peak effect of floseauhran were decreased
by 3.5 t 1.3, 2 .8 t 0.7 and 5 .1 t 1 . .3 stun Hg, respectively (all
p < 0.01). Systemic vascular resistance had decreased by 585 t
95 dynes-s-cm" g , cardiac index had increased by 0 .5 t 0.1 liters/mis.
per m2 and heart rate had increased by 10 ± 2 beatslmin (all p < .
0.001).
Conclusions. The arterial and venous vasodilator flosequinan
exerts both short- and long-term sustained hemodynamic effects In
patients with heart failure receiving angiotensin-converting en-
zyme inhibitors.
(J Am Coll Cordial 199.1 ;22:963--7)
Flosequinan is a vasodilator that has actions similar to
those of the hydralazine-isosorbide dinitratc combination,
exerting balanced arterial and venous vasodilation in pa-
tients with congestive heart failure (3). After short-term
administration of flosequinan in patients not receiving
angiotensin-converting enzyme inhibitors, left ventricular
filling, mean arterial and right atria] pressures decrease, and
there is a consequent rise in cardiac index . After long-term
therapy, the same response is observed (4,5) . These benefi-
cial hemodynamic effects produce improved exercise toler-
ance and decreased symptoms of heart failure (6) .
Patients receiving angiotensin-converting enzyme inhibi-
tors might have a similar clinical response to flosequinan if
the drug exerts beneficial hemodynamic effects in such
patients; however, because the extent of vasodilation in-
duced by an agent is related to the basal vasoconstrictive
state of the patient (7), patients receiving angiotensin-
conveiti e, enzyme inhibitors might react differently to flose-
quinan (and other direct-acting vas- dilators) t
:ian would
those not being treated with these agents . Yet . there have
been no previous evaluations of the loug-term hemodynamic
effects of any direct-acting vasodilator in patients with heart
failure receiving an angiotensin-converting enzyme inhibi-
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for. Using pulmonary artery thermodilution catheters, we
therefore assessed both the short- and long-term hemody-
namic effects of flosequinan in patients receiving captopril .
Methods
y patients. We studied 47 patients with severe left
ventricular dysfunction who were referred for treatment of
refractory heart failure . There were 35 men and 12 women,
aged 21 to 79 years (mean age 61 w 2). All patients had a left
ventricular ejection fraction <40% by radionuclide angiog-
raphy (range 5% to 36%, mean 1S ± 1%) . The cause of heart
failure was ischemic heart disease or dilated cardiomyopa-
thy ; 28 patients were in New York Heart Association
functional class III and 19 were in class IV . All patients had
received constant doses of digitalis and diuretic agents for at
least 5 days and had received angiotensin-converting en-
zyme inhibitors for at least 2 months. They were receiving
captopril three times daily in a total daily dose of 37.5 mg (4
patients), 75 mg (20 patients), 112 .5 mg (2 patients) or 150 mg
(21 patients) . Previous therapy with other vasodilator drugs
was withdrawn for m5 days before entry into the study .
Another 10 patients were initially entered into the study but
were withdrawn before final evaluation because of death (7
patients), rash (I patient), patient refusal (1 patient) and
problems with the Swan-Ganz catheter (1 patient) .
Shat-term hemodynamic measurements. Right heart
catheterization and arterial cannulation were performed at
least 12 h before hemodynamic assessment. All cardioactive
medications were withheld for a8 h, and hemodynamic
variables were measured using previously described proce-
dures (8). The baseline measurements were made before the
administration of any doses of flosequinan .
Patients were then randomized to receive 50, 100 or
150 mg of flosequinan daily in addition to their previous
medications. because the flint effects of flosequinan are not
apparent after administration of only a single dose of the
drug (9), the short-term hemodynamic assessment of Rose .
quinan was performed on day 2 of flosequinan administra-
tion. Hemodynamic measurements were obtained before
administration of flosequinan and periodically for 4 h . No
other medications were given on that day until completion of
hemodynamic assessment.
L011119-term treatment. After the short-term measure-
ments were made, patients were discharged from the hospi-
tal . For the next 8 weeks, they received their usual prestudy
medications in addition to the daily flosequinan dose to
which they were randomized.
Loin-tee
namic min ements. Patients were
readtnittedto the hospital 8 weeks after baseline assessment,
and hemodynamic measurements were obtained as initially
performed
. Long-term pretreatment values were obtained
12 h after placement of the catheter and the effects of drug
administration were assessed the following day in a manner
analogous to that of the initial evaluation .
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Flgure 1 . Mean arterial, left ventricular filling and right atrial
pressures before and after 8 weeks of therapy with flosequinan in 47
patients with severe heart failure receiving long-term treatment with
captopril . Solid bars indicate the values for each hemodynamic
variable before flosequinan administration; open bars indicate values
I h after the drug was given ; "p < 0.001 compared with the period
before flosequinan dosing for that evaluation period ; p values shown
compare short-term variables with those obtained before any flose-
quinan therapy . After long-term flosequinan therapy, a dose of this
drug exerted effects iimilar to those initially seen .
Data analysis . Statistical comparisons were made uc :ng
the two-tailed Student t test for paired data . The values
obtained I h after flosequinan administration were used to
evaluate the short-term effect of drug administration . The
mean value * SEM are given where appropriate.
Results
Despite long-term treatment with captopril, the patients
studied were severely ill as demonstrated by the markedly
abnormal hemodynamic variables assessed before flose-
quinan administration (Fig. 1 and 2) . The mean left ventric-
ular filling pressure was 24 ± 1 .1 mm Hg and the mean
cardiac index was 1 .8 ± 0.1 liters/min per m2.
Short-term flosequinan administration caused significant
vasodilation and an increased heart rate . Mean arterial, right
atria/ and left ventricular filling pressures decreased by 6 .4 ±
1 .1, 3 .8 ± 0.5 and 7.3 ± 0.7 mm Hg, respectively (all p <
0.001) (Fig. 1). Cardiac index increased by 0 .5 ± 0.1 liters/
min per m2; systemic vascular resistance decreased by 616 ±
105 dynes-s-cm -5 and heart rate increased by 4 ± 1 beats/
min (all p < 0.001) (Fig, 2) .
After 8 weeks of therapy with flosequinan, but before
administration of the daily dose of the drug, cardiac index had
increased by 0.4 ± 0.1 liters/min per m2 (p < 0.001), systemic
vascular resistance had decreased by 392 ± 104 dynes-s-cm -5
(p < 0.05) and heart rate had increased by 9 ± 2 beats/ndn
(p < 0.001). Nevertheless, the vasodilator effect of a dose of
flosequinan persisted (Fig. 1 and 2). After administration of
flosequinan, almost all variables were similar to those observed
after short-term administration of flosequinan 8 weeks earlier .
Only heart rate was significantly faster (p < 0 .01). Compared
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Figure 2. Effects of flosequinan administration on cardiac index .
systemic vascular resistance and heart rate in 47 patients with
severe heart failure receiving long-term treatment with captopril .
Short-term administration of flosequinan increased heart rate and
cardiac index and decreased systemic vascular resistance (Vasc
Resist). After long-term flosequinan therapy, a dose of this drug
exerted effects similar to those initially seen . Symbols as in Figure 1 .
with pretreatment baseline measurements, mean arterial,
right atrial and left ventricular filling pressures at the
peak effect of flosequinan (after 8 weeks of long-term admin-
istration) had decreased by 3 .5 ± 1 .3, 2 .8 ± 0.7 and 5 .1
1 .3 mm Hg, respectively (alt p < 0.01). Systemic vascular
resistance had decreased by 585 ± 95 dynes-s-em -5, cardiac
index had increased by 0.5 ± 0.1 liters/min per m2 and heart
rate had increased by 10 ± 2 beats/min (all p < 0.001).
Clinically, by functional classification, 22 patients im-
proved by one class and 5 improved by two classes . The
condition of three patients deteriorated, and functional class
was unchanged in the remaining 17 patients .
Table I demonstrates the response to flosequinan therapy
in patients who received the three different doses . Although
not statistically significant, the highest dose, 150 mg, pro-
Table l . Change in Hemodynamic Variables as Related to Dose
of Fooeequinan
Values presented are mean value ± SEM amd show the differences
between pretreatment values and the peak effect (1 h after drug administra-
tion) after 8 weeks of !otug-term flosequinan therapy .
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duced a greater decrease in mean arterial, left ventricular
filling and right atrial pressures than either of the other two
doses. In addition, increasing doses of flosequinan produced
larger increases in cardiac index and heart rate and greater
decreases in systemic vascular resistance .
Discussion
This is the first study to demonstrate, using invasive moni-
toring, an additive hemodynamic effect of long-term adminis-
tration of a vasodilator in patients receiving angio€ensin-
converting enzyme inhibitors . The hemodynamic effects of
flosequinan persisted ; the variables measured after drug admin-
istration after 8 weeks of long-term flosequinan therapy were
similar to those observed with short-term drug administration
.
These findings support the concept that long-term therapy with
a vasodilator may be effective in patients receiving angiotensin-
converting enzyme inhibitors.
Hemodynamic effects of flosequinan . The short-term he-
modynamic effects of flosequinan are predominantly related
to its arterial and venous vasodilator effects . Mean arterial
and both right atrial and left ventricular filling pressures
decrease markedly after a single dose of flosequinan (3,10),
with the peak decrease in systemic vascular resistance
occurring between I and 2 h after dose administration . A
dose-related positive inotropic effect of flosequinan has also
been seen (11,12), but its importance at therapeutic concen-
trations in patients with heart failure is still unknown . The
increased cardiac index seen after flosequinan administra-
tion is probably predominantly secondary to vasodilation .
Heart rate also increases with flosequinan, although the
mechanism is unknown ; it does not appear to be related to
reflex neurohormoaal activation (13) .
After long-term treatment with flosequinan, a dose of
flosequinan causes vasodilation (4,14), but the short-term
effect i s smaller than that seen after the first dose of
flosequinan . It has been suggested that this attenuated he-
modyntunic response to flosequinan administration may be
secondary to activation of the renin-angiotensin system . The
present study counters this view because the response ob-
served in our patients with inhibition of the renin-angiotensin
system was very similar to that previously observed in patients
not receiving angiotensin-converting enzyme inhibitors.
Rather, the similarity of the peak hemodynamic effects of
flosequinan administration both before and after long-term
therapy with flosequinan supports another explanation . Persis-
tent vasodilation secondary to the long-acting, hemodynami-
cally active metabolite (12) probably prevents additional
flosequinan-induced vasodilation to the same extent possible
before accumulation of this metabolite .
A long-term effect of the sulfone metabolite of flose-
quinan is also suggested by comparison of the hemodynamic
variables measured before administration of a dose of the
drug both before and after long-term flosequinan therapy .
Analysis of hemodynamic variables obtained 8 weeks apart
is fraught with danger in an uncontrolled study
; any actions
Flosequinan Dose
50 mg
(n
= Is)
1(0 mg
(n = 13)
130 mg
(n = 16)
Cardiac index
(literslmin per m2
)
+0.53
±
0.1 +0.53 ± 0.1 +0.59 ± 0.1
Mean arterial pressure
(mm Hg)
-3.9 t 1 .6 -2 .2 t 3 .3 -4
.1
± 2
.0
Right atrial pressure
(mm Hg)
-2 .0
±
0,9 -3 .2 ± 1 .0 -3 .2 ± 1 .4
Left ventricular filling
pressure (mm Hg)
-5.6 t 1 .9 -3.7 ± 2.4 --3
.8
± 2 .6
Heart rate (beatslmin) +5
t
3 +8
± 4 +17 t 3
Systemic vascular resistance
(dynes's •cm-s)
-493 ± 109 -529 ± I -733 ± 203
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of fosequinan might be
hidden by the natural course of the
disease and by the fluctuations that occur over a 2-month
period
. It appears, however, that after 2 months of treat-
ment, but before dosing, both heart rate and cardiac index
are greater than those initially seen, and systemic vascular
resistance is decreased .
Ann at Noacquinan to atigiotensin-converting
enzyme
Wftm
The present study demonstrates a clear, persis-
tent hemodynamic effect of flosequinan administered for 8
weeks to patients receiving angiotensin-converting enzyme
inhibitors. Although this effect appears similar to those
previously reported in patients not receiving angiotensin-
converting enzyme inhibitors, a number of observations are
interesting . First, even the smallest dose of 50 mg produced
a hemodynamic response . In previous studies demonstrating
efficacy of flosequinan in patients with heart failure, the dose
administered was L-100 mg. It is thus unknown whether the
smaller 50-mg dose would also be effective in patients not
receiving angiotensin-converting enzyme inhibitors . How-
ever, activation of the renin-angiotensin system can limit the
hemodynamic actions of vasodilators (15), and prevention of
this activation could theoretically increase the vasodilator
response to a drug. Thus, the inability of patients receiving
angiotensin-converting enzyme inhibitors to activate the
renin-angiotensin system could potentially prevent attenua-
tion of the vasodilator effects of flosequinan and enhance the
actions of low doses of the drug .
In certain circumstances, the ability to dilate the vascu-
lature is related to the extent of basal vasoconstriction (7) .
and patients receiving angiotensin-converting enzyme inhib-
itors might therefore be expected to respond less intensively
to vasodilators . However . our data clearly demonstrate that
the vasodilation caused by angiotensimconverting enzyme
inhibition does not limit the extent of vasodilation induced
by flosequinan . The actions of flosequinan reported in this
study are as great as those previously reported in patients
not receiving angiotensin-converting enzyme inhibitors,
Dose resp~. The present study supports the concept
that increasing the dose of flosequinan causes an increased
hemodynamic effect. Although the study group was too
small to show statistically significant differences among
doses, the trend is clear ; however, these data should not be
interpreted as demonstrating the optimal dose of flose-
quinan. The dose causing the largest hemodynamic effect
may not be the optimal clinical dose . This has been
demonstrated with phosphodiesterase inhibitors (16) and
angiotensin-converting enzyme inhibitors (17) and could be
true with Iosequinan as well . Still, the dose-response curve
does support the conclusion that Oosequinan continues to
exert hemodynamic actions after 8 weeks of therapy . Even
though the present study was not placebo controlled, both
the marked hemodynamic charges seen with the administra-
tion of f osequinan after 8 weeks of therapy and the relation
of this response to the various administered doses demon-
strate the long-term hemodynamic actions of flosequinan .
Relevance to other vasodilators . The mechanism of action
of flosequinan has not been fully elucidated but may be
related to the dose-dependent attenuation of the inositol
triphosphate pathway seen in vitro (18) . Flosequinan is not a
phosphodiesterase inhibitor, and it does not act via actions
on cyclic guanosine monophosphate or cyclic adenosine
monophosphate (19) . The unique mechanism of flosequinan
makes extrapolation of the results of this study difficult .
Nevertheless, there are data to suggest that other vasodila-
tors may be similarly beneficial. Although this is the first
demonstration of the long-term effects of any dimci-actinr,
vasodilator in patients receiving angiotensin-converting en-
zyme inhibitors, it has previously been demonstrated that
the hemodynamic effects of both hydralazine and nitroprus-
side are additive to those of short-term captopril administra-
tion (20,21).
The present study demonstrates that even in patients with
long-term angiotensin-converting enzyme inhibition, marked
vasodilation can be produced with a direct-acting vasodila-
tor. This finding supports the concept that vasodilators can
successfully be added to the drug regimen of patients with
heart failure who are receiving angiotensin-converting en-
zyme inhibitors .
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